A Two-Cohort, Open-Label, Single and Multiple Dose Pharmacokinetic Study of 90 mg and 180 mg Doses of AZD6140 [ticagrelor]in Healthy Chinese Volunteers Living in China

Trial Profile

A Two-Cohort, Open-Label, Single and Multiple Dose Pharmacokinetic Study of 90 mg and 180 mg Doses of AZD6140 [ticagrelor]in Healthy Chinese Volunteers Living in China

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Ticagrelor (Primary)
  • Indications Cardiovascular disorders; Embolism and thrombosis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 21 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top